Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Why did the two price monitering extensions RNS come out so late in the day or was it this site again?
Actually, probably yes looking at TILS site
https://ir.tizianalifesciences.com/news-releases/news-release-details/tiziana-life-sci-plc-second-price-monitoring-extn-15
Armchair Trader, nothing new
https://www.thearmchairtrader.com/tiziana-life-sciences-preps-spin-out-of-genomics-business/
Tiziana Life Sciences (AIM: TILS / NASDAQ: TLSA) is planning to consult shareholders on the demerging and separate listing of its genomics-based personal medicine business. The NASDAQ-listed clinical stage biotechnology enterprise says it will list StemPrintER as a separate entity, but will need shareholder approval to do so.
StemPrintER has been trialled in Milan at the European Institute of Oncology and at the Royal Marsden and Queen Mary University hospitals in London. The technology aims to predict the likelihood of recurrence in breast cancer. The results of the trials and the progress being made in the research has convinced Tiziana Life Sciences to push for a separate listing for StemPrintER.
Tiziana said that the move would help to secure separate financial resources for the project and help to accelerate the development of the genomic test. The new entity would be focused more specifically on the personalised medicine market, allowing the parent company to continue to concentrate on its core biotechnology and pharmaceutical work.
Nano One receives further government funding for battery materials project
Tiziana’s board said last week they could consult shareholders at the company’s next AGM, as the de-merger would involve a capital reduction. There is no guarantee that such approval will be forthcoming. Existing shareholders in Tiziana Life Sciences would benefit from stock in the new StemPrintER venture. The firm did confirm that StemPrintER, or whatever it ends up being called, would remain part of the same group.
Volumes in Tiziana Life Sciences shares have picked up dramatically since the middle of March and we have seen high volatility in the share price. Shares were trading at around GBR 30-40 as late as 3 April, before setting off on a march which has taken them to today’s price of GBR 107.
Tiziana remains a diversified biotech play: it has a number of treatments on the go, many of which are much further down the line than StemPrintER. It focuses much of its work around its lead compound, milciclib, a molecule which blocks the action of CDK (cyclin-dependent kinases) enzymes. These are involved in cell division among other activities.
It is also working on the development of foralumab, the only full human anti-human CD3 antibody in clinical development in the world. It has potential application in a wide range of autoimmune and inflammatory diseases, such as MS and type 1 diabetes, among many others.
...it’s mentioned at the end of this article, but they may have it wrong as it is a Sunday!
https://www.thearmchairtrader.com/tiziana-life-sciences-preps-spin-out-of-genomics-business/
Where did people find out that the AGM is on the 31st, I only ask as I haven't seen this confirmed anywhere so think it's just speculation?
Many thanks in advance.